Alopecia Areata Clinical Trial
Official title:
Phase 2 Double Blind Randomized Placebo Controlled Trial of Topical Crisaborole in Patients With Mild-to-Moderate Alopecia Areata
NCT number | NCT04299503 |
Other study ID # | 13289 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | March 6, 2020 |
Est. completion date | December 2022 |
Verified date | January 2022 |
Source | Tufts Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to determine whether topical crisaborole improves hair growth in alopecia areata.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2022 |
Est. primary completion date | March 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: 1. Signed and dated informed consent document indicating the subject has been informed of all aspects of the study. 2. Subject is willing and able to comply with scheduled visits, treatment plan, study drug administration, and other study procedures. 3. Clinical diagnosis of alopecia areata with at least one lesion 1 cm in diameter and no more than 20% of total scalp surface area. 4. Females of child-bearing potential agree to use a reliable method of birth control or remain absent during the study and for at least 4 weeks following the last dose of the assigned treatment. 5. If receiving concomitant medications for any reason, must be on a stable regimen and willing to stay on a stable regimen. 6. All treatments for alopecia areata are prohibited during the course of the study. If subjects received any of the following treatments, the minimum criteria are observed: - Must be discontinued for at least 12 weeks prior to Baseline: o Any investigational or experimental therapy or procedure for alopecia areata; - Exception: Investigational biologics should be discussed with Sponsor to confirm period of discontinuation required. Must be discontinued for at least 8 weeks prior to Baseline: o Laser or light based alopecia areata treatments - Must be discontinued for at least 4 weeks prior to Baseline: - Immunomodulating or immunosuppressive oral medications (corticosteroids, methotrexate, cyclosporine, etc.) Subjects who require these medications during the study (e.g. use of corticosteroids for a chronic obstructive pulmonary disease exacerbation) will be terminated from the study. - Injections of steroids to alopecia areata areas - Contact sensitization treatment - Oral minoxidil - Patients already taking finesteride for at least 3 months to treat conditions in addition to or other than hair loss (benign prostate hypertrophy, hormonal suppression, etc.) may continue on this medication so long as the dose remains stable throughout the study. - Must be discontinued for at least 2 weeks prior to Baseline: - Topical treatments that may affect alopecia areata, e.g., corticosteroids, topical tacrolimus/pimecrolimus, retinoids. Use of these medications in non-AA areas, for non-AA conditions is allowed. - Hair regrowth products containing minoxidil - Use of any prior and concomitant therapy not listed above which, in the opinion of the PI may interfere with the objective of the study, within 60 days prior to the Screening Visit is prohibited Exclusion Criteria: 1. Other skin conditions that, in the opinion of the PI would interfere with evaluation of alopecia areata. Conditions may include other types of hair loss, including discoid lupus, lichen planus pilaris, frontal fibrosing alopecia, cicatricial alopecia, and trichotillomania (hair pulling). 2. Pregnant/breastfeeding females, or females of childbearing potential not using highly effective contraception. Women of childbearing potential must test negative for pregnancy and use contraception for at least four weeks after last dose of drug. 3. Current or recent history of clinically significant medical or psychiatric condition, which, in the judgment of the principal investigator, may increase risk associated with the study participation or drug administration. Examples include, but are not limited to, recent infections or injuries of the scalp. 4. Have a history of infection requiring parenteral or oral or topical antimicrobial therapy within 2 weeks prior to baseline. 5. Received a prohibited concomitant medication within 7 days or 5 half-lives (whichever is longer) prior to baseline visit. 6. Subjects who have had an allergic reaction (e.g. urticarial, anaphylactic) to crisaborole will be excluded. 7. Participated in a trial for a topical or oral JAK inhibitor. JAK inhibitors are thought to improve alopecia areata, and sometimes the effects of JAK inhibitors can last long after treatment is completed. Past treatment with these agents could confound the results of crisaborole's effectiveness for alopecia. 8. Is currently on an oral PDE4 inhibitor or oral JAK inhibitor. PDE4 inhibitors and JAK inhibitors have been theorized to improve alopecia. Treatment with these agents could confound our results on the effectiveness of crisaborole for alopecia areata. 9. Have participated in other research studies of investigational products within 4 weeks or 5 half-lives (whichever is longer) of the investigational product prior to baseline. Subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study. 10. Subjects who are investigational site staff members or relatives of those site staff members or subjects who are Sponsor employees directly involved in the conduct of the trial. 11. In the opinion of the investigator or Sponsor, the subject is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle guidelines. |
Country | Name | City | State |
---|---|---|---|
United States | Tufts Medical Center, Department of Dermatology | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Tufts Medical Center | Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Severity of Alopecia Tool (SALT) Score Double-Blind Period | percent change in Severity of Alopecia Tool (SALT) score from baseline to Week 12. The range in score is 0% (no hair loss) to 100% (complete hair loss). | Baseline to Week 12 | |
Primary | Severity of Alopecia Tool (SALT) Open-Label Period | percent change in Severity of Alopecia Tool (SALT) score from baseline to Week 24. The range in score is 0% (no hair loss) to 100% (complete hair loss). | Baseline to Week 24 | |
Secondary | Severity of Alopecia Tool (SALT)50 Response Double-Blind Period | Greater than or equal to 50% reduction in Severity of Alopecia Tool (SALT) score response in terminal hair at Week 6 and Week 12. The range in score is 0% (no hair loss) to 100% (complete hair loss). | Week 6 and Week 12 | |
Secondary | Severity of Alopecia Tool (SALT)50 Response Open-Label Period | Greater than or equal to 50% reduction in Severity of Alopecia Tool (SALT) score response in terminal hair at Week 24. The range in score is 0% (no hair loss) to 100% (complete hair loss). | Week 24 | |
Secondary | Severity of Alopecia Tool (SALT)90 Response Double-Blind Period | Greater than or equal to 90% reduction in Severity of Alopecia Tool (SALT) score response in terminal hair at Week 6 and Week 12. The range in score is 0% (no hair loss) to 100% (complete hair loss). | Week 6 and Week 12 | |
Secondary | Severity of Alopecia Tool (SALT)90 Response Open-Label Period | Greater than or equal to 90% reduction in Severity of Alopecia Tool (SALT) score response in terminal hair at Week 24. The range in score is 0% (no hair loss) to 100% (complete hair loss). | Week 24 | |
Secondary | alopecia areata Physician Global Assessment (aaPGA) Double-Blind Period | achieving an alopecia areata Physician Global Assessment (aaPGA) score of 3 or above at Weeks 6 and 12; (0 =no regrowth; 1 = <25% of regrowth; 2 = 25%-49% of regrowth; 3 = 50%-74% of regrowth; 4 = 75%-99% of re- growth; 5 = 100% of regrowth) | Week 6 and Week 12 | |
Secondary | alopecia areata Physician Global Assessment (aaPGA) Open-Label Period | achieving an alopecia areata Physician Global Assessment (aaPGA) score of 3 or above at Week 24; (0 =no regrowth; 1 = <25% of regrowth; 2 = 25%-49% of regrowth; 3 = 50%-74% of regrowth; 4 = 75%-99% of re- growth; 5 = 100% of regrowth) | Week 24 | |
Secondary | Alopecia Areata Symptom Impact Scale (AASIS) Double-Blind Period | percent change from Baseline in the Alopecia Areata Symptom Impact Scale (AASIS) at Week 6 and Week 12 | Week 6 and Week 12 | |
Secondary | Alopecia Areata Symptom Impact Scale (AASIS) Open-Label Period | percent change from Baseline in the Alopecia Areata Symptom Impact Scale (AASIS) at Week 24 | Week 24 | |
Secondary | Dermatology Life Quality Index (DLQI) Double-Blind Period | Percent change from Baseline in the Dermatology Life Quality Index (DLQI) at Week 6 and Week 12 | Week 6 and Week 12 | |
Secondary | Dermatology Life Quality Index (DLQI) Open-Label Period | Percent change from Baseline in the Dermatology Life Quality Index (DLQI) at Week 24 | Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05051761 -
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
|
Phase 3 | |
Active, not recruiting |
NCT03570749 -
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
|
Phase 2/Phase 3 | |
Completed |
NCT02812342 -
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
|
Phase 2 | |
Completed |
NCT02350023 -
Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata
|
Phase 4 | |
Completed |
NCT02018042 -
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
|
Phase 2 | |
Terminated |
NCT01898806 -
Intralesional Steroids in the Treatment of Alopecia Areata
|
Phase 4 | |
Recruiting |
NCT04011748 -
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
|
Phase 2 | |
Terminated |
NCT04517864 -
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
|
Phase 2 | |
Not yet recruiting |
NCT05803070 -
Topical Cetirizine in Treatment of Localized Alopecia Areata
|
||
Not yet recruiting |
NCT05496426 -
A Study of KL130008 in Adults With Severe Alopecia Areata
|
Phase 2 | |
Completed |
NCT04147845 -
Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata
|
N/A | |
Terminated |
NCT03325296 -
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
|
Phase 2 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Enrolling by invitation |
NCT05745389 -
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
|
||
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06087796 -
Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.
|
Phase 1 | |
Withdrawn |
NCT03532958 -
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
|
Phase 2 | |
Recruiting |
NCT02604888 -
Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females
|
N/A | |
Terminated |
NCT01385839 -
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
|
N/A | |
Completed |
NCT00408798 -
Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin
|
N/A |